Murat O. Arcasoy

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Haematologica · 2015 · 329 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injury

Gary L. Wright, Paul Hanlon, Khalid Amin et al. · The FASEB Journal · 2004 · 225 citations

Life Sciences, Pharmacology, Physiology +13

Lung transplantation in telomerase mutation carriers with pulmonary fibrosis

Leann Silhan, Pali D. Shah, Daniel C. Chambers et al. · European Respiratory Journal · 2014 · 190 citations · Full text

Medicine, Genetics, Hematology +16